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Abstract:	
	Whole	body	biodistribution	of	100	nanometer	sized	polymer	micellar	nanoparticles	(NPs)	was	determined	following	intranasal	administration	using	PET/CT	imaging	on	a	clinical	scanner.	Nanoparticles	labeled	with	Zirconium	89	were	administered	intranasally	or	intravenously	to	Sprague	Dawley	rats	followed	by	serial	ex	vivo	PET/CT	imaging	in	a	clinical	scanner.	At	30	minutes	and	1	hour	following	intranasal	delivery,	the	animals	were	sacrificed	and	placed	 in	 the	PET/CT	scanner.	 Images	were	acquired	and	 transferred	 to	a	workstation	for	post-processing.	3D	regions	of	interest	were	constructed.	A	different	set	of	animals	were	used	 for	ex	vivo	verification.	These	animals	were	also	administered	100	nm	polymer	micellar	NPs	and	sacrificed	 at	 30	min	 and	 1	 hr	 following	 intranasal	 or	 intravenous	 delivery	 via	 intra-cardiac	 perfusion.	Various	organs,	including	brain,	lungs,	heart,	liver,	spleen,	stomach	and	intestines,	were	procured	following	exsanguination.	A	gamma	counter	determined	activity	in	each	organ	for	comparison	with	corresponding	PET/CT	region	of	interest	activity	measurements.	The	ex	vivo	measurements	of	activity	were	consistent	with	 the	 image-based	 value	 determinations.	 Use	 of	 a	 clinical	 PET/CT	 scanner	 is	 a	 feasible	 means	 to	determine	the	temporal	and	spatial	distribution	of	radiolabeled	agents	after	intranasal	and	intravenous	delivery.	This	work	may	allow	for	quantitative	in	vivo	testing	of	new	radionanotheranostic	agents.					
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1.	Introduction:	Central	nervous	system	(CNS)	disorders	are	often	difficult	to	treat	since	most	drugs	cannot	cross	the	blood-brain	barrier	(BBB).	Continued	development	of	alternate	pathways	for	delivery	and	fate	of	drugs	that	can	bypass	the	BBB	is	needed.	Intranasal	drug	delivery	(INDD)	is	a	promising	alternative	to	other	forms	of	drug	delivery	in	its	potential	for	CNS	treatment	since	it	is	relatively	non-invasive,	avoids	first	pass	metabolism	and	 side	 effects	 can	 be	minimized	 because	 smaller	 drug	 concentrations	 are	 used.	 Because	 of	 its	 non-invasive	nature,	there	is	reduced	risk	of	infection	and	disease	transmission.	Nasal	spray	formulations	are	easy	to	administer	and	can	be	performed	at	home	by	the	patient.			So	far,	a	limited	number	of	promising	agents	have	progressed	beyond	pre-clinical	investigation.	Even	with	the	drugs	that	are	in	clinical	trials,	the	specific	mechanism	of	nose	to	brain	transport	is	not	defined	in	most	cases.	 Key	 to	 overcoming	 these	 challenges	 and	 furthering	 the	 field	 of	 INDD	 is	 to	 develop	 a	 reliable,	informative	and	non-invasive	methodology	for	better	understanding	the	nose	to	brain	delivery	pathway	using	in	vivo	advanced	imaging	both	at	the	clinical	and	pre-clinical	levels.	Use	of	a	dedicated	small	animal	positron	 emission	 tomography/computed	 tomography	 (PET/CT)	may	not	 be	 readily	 available	 at	 some	institutions	 and	 is	 costly	 to	 install	 and	maintain.	 An	 acceptable	 alternative	 that	 has	 been	 investigated	previously	is	through	the	use	of	a	clinical	PET/CT	(1).		Drug	administration	and	delivery	are	essential	steps	in	pharmacotherapy	(2)	(3)	(4),	where	imaging	can	localize	 and	 measure	 tailored	 agents	 such	 as	 multifunctional	 nanoparticles	 or	 nanotheranostics	 to	determine	their	fate	(5).			Nanoparticles	(NPs)	are	typically	range	 from	10	to	100	nanometers	 in	diameter	and	can	potentially	be	targeted	 at	 specific	 molecular	 sites	 by	 surface	 ligands.	 Polymer-based	 NPs	 can	 possess	 optimal	characteristics	 of	 small	 size,	 safety,	 biodegradability,	 and	 customizable	 surface	 functionalization	 that	facilitate	drug	delivery	across	many	biological	cell	barriers,	including	the	blood	brain	barrier	and	the	nose-brain	 barrier	 (6).	 Polymer-based	 NPs	 have	 been	 developed	 for	 drug	 delivery	 and	 have	 received	 FDA	approval	for	safety	(7).	When	delivered	or	implanted	in	the	body,	PLA,	PGA	and	PLGA	undergo	hydrolysis	and	eventually	turn	into	water	and	carbon	dioxide	through	citric	acid	cycle	(8).			Clinical	multimodality	 imaging	of	 intranasal	polymeric	nanoparticle	(NP)	administration	via	 intra-nasal	drug	delivery	(INDD)	was	used	for	whole	body	visualization,	localization	and	measurement	in	the	normal	adult	 Sprague	 rat.	 The	 purpose	 of	 this	 study	was	 to	 compare	 intranasal	 and	 intravenous	whole	 body	biodistribution	 using	 PET/CT	 imaging	 in	 rats.	 A	 radiolabeled	 polymeric	 nanoparticle	 administered	intranasally	and	intravenously	was	evaluated	at	two	early	time	points.	This	work	was	done	to	demonstrate	a	means	for	quantitative	in	vivo	pre-clinical	testing	of	new	radio-nanotheranostic	agents.			
2.	Materials	and	Methods:	
	
2.1.	Animals		The	protocol	for	animal	experiments	was	approved	by	the	institutional	Animal	Care	and	Use	Committee	(IACUC).	Male,	Sprague-Dawley	rats	(300-500	gm)	(Harlan	Industries,	Indianapolis,	IN)	were	maintained	under	 controlled	 environmental	 conditions	 (23	 °C,	 12h	 light/dark	 cycle)	with	 free	 access	 to	 standard	laboratory	chow	and	tap	water	prior	to	INDD.	A	total	of	20	animals	were	utilized	for	this	feasibility	study	with	6	animals	undergoing	2	hr	of	continuous	PET/CT	imaging	(N=3	for	INDD	experimental	group	and	N=3	for	intravenous	control	group)	and	12	animals	undergoing	gamma	counting	following	brain	isolation	and	tissue	dissection	(N=3	for	1	Hr	following	INDD	experimental	treatment,	N=3	for	1	Hr	following	IV	control	
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treatment,	N=5	 for	2	hr	 following	 INDD	experimental	 treatment	and	N=3	 for	2	hr	 following	 IV	 control	treatment).	
	
	Figure	1.	INDD/IV	workflow.	In	Phase	1,	the	100	nm	PLA-DSPE-PEG	NPs	were	fabricated	(A)	and	tagged	with	89Zr	(B)	and,	underwent	morphologic	and	size	characterization	in	vitro	using	transmission	electron	microscopy	(C).	In	phase	2,	the	NPs	were	delivered	intranasally	(D)	or	intravenously	(E)	which	served	as	the	control	comparison.	In	Phase	3,	the	rats	were	euthanized,	and	transferred	to	the	clinical	PET/CT	unit	(G)	where	images	were	acquired	and	processed	(F).	Atlas-base	segmentation	and	various	organ	ROI	measurements	(brain,	lungs,	liver,	spleen,	GI	tract,	bladder)	were	obtained.	In	phase	4,	the	organs	listed	above	were	procured	and	analyzed	in	a	gamma	counter	(J).	Statistical	analysis	and	comparison	was	performed	between	the	PET/CT	data	and	gamma	data.	
	
2.2.	Nanoparticles	Polylactic	acid	(PLA)	polymer	based	nanoparticles	(NPs)	coated	with	polyethylene	glycoal	(PEG)	chains	containing	20%	end	amino	groups	(PLA-PEG	NPs)	were	synthesized	(Bio	Ma-Tek,	Bio	Materials	Analysis	Technology	Inc.,	http://www.bioma-tek.com/,	Hsinchu	County,	Taiwan).	The	individual	compounds	used	to	fabricate	the	nanoparticles	are	listed	in	Table	1.	These	NPs	were	characterized	in	vitro	using	dynamic	light	 scattering	 (DLS),	 zeta	 potential	 measurement,	 and	 transmission	 electron	 microscopy.	 The	 NP	characterizations	 were	 performed	 consistent	 with	 ISO	 13014	 (9).	 The	 NPs	 were	 shipped	 dry	 to	 our	laboratory	 in	 Chicago	 where	 they	 were	 reconstituted	 into	 a	 sterile	 aqueous	 suspension	 prior	 to	experimental	use	in	animals.				 	
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Table	1.			Nanoparticle	Materials		 Material	 Company	Ammonium	thiocyanate	 Sigma	Aldrich	 	DiR	(1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine	iodide),	PLA	[poly(D,L-latide),	MW:	75,000-120,000]	 Sigma-Aldrich	Iron	chloride	hexahydrate	 Sigma-Aldrich	Chloroform	 J.T.	Baker	Dichloromethane	 J.T.	Baker	Tetrahydrofuran	 J.T.	Baker	DSPE-PEG2000	{1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy	(polyethylene	glycol)-2000]}	 Avanti	Polar	Lipids	DSPE-PEG2000-NH2	{(1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino	(polyethylene	glycol)-2000])	 Avanti	Polar	Lipids		
2.2.1.	PLA-PEG	nanoparticle	preparation	Polylactic	acid	–	polyethylene	glycol	(PLA-PEG)	nanoparticles	were	prepared	as	previously	reported	with	modifications	 (10).	 Briefly,	 5	 mg	 of	 PLA,	 8	 mg	 of	 DSPE-PEG2000	 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene	glycol)-2000),	2	mg	of	DSPE-PEG2000-NH2,	and	0.1	mg	of	DiR	were	dissolved	in	0.5	ml	dichloromethane,	and	then	dropped	into	3	ml	double-distilled	water.	 	The	mixed	 solution	was	 emulsified	 over	 an	 ice	 bath	 for	 1	min	 using	 a	microtip	 probe	 sonicator	 (XL-2000,	Misonix)	at	7	W	output.		The	dichloromethane	was	removed	by	rotary	evaporation	to	harden	nanoparticles.		After	centrifugation	at	13,500	xg	 for	10	min,	pellets	were	discarded	and	nanoparticles	suspension	was	washed	three	times	with	10%	sucrose	solution	by	30	kD	MWCO	ultrafiltration	(Vivaspin	6,	GE	Healthcare).		The	 purified	 nanoparticles	were	 lyophilized	 and	 stored	 at	 -20⁰C.	 	 	 The	materials	 used	 in	 nanoparticle	handling	and	their	sources	are	listed	in	Table	1.	The	physicochemical	characteristics	of	these	nanoparticles	were	determined	and	are	summarized	in	Table	2.			 	
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Table	2.			PLA-PEG	NP	physiochemical	characterization	
	 Parameter		 Result	1.Particle	size/size	distribution	 	 					Mean	diameter	(TEM)	 41.1	nm	(n=506)					Hydrodynamic	diameter	(DLS)	 97.1	nm					Polydispersity	(DLS)	 0.19	2.Aggregation/agglomeration	state	 No	aggregation/agglomeration	3.Shape	(TEM)	 Fluffy	sphere	(negative	stain)	4.Specific	surface	area	 Not	applicable	5.Composition	(each	eppendorf)	 4.67	mg	PDA01	+	50	mg	sucrose					DiR	 27.1	μg					DSPE-PEG2000	 3.2	mg					DSPE-PEG2000-NH2		 64.7	μg	(estimated)					PLA	 1.41	mg					Sucrose		 50	mg	(estimated)	6.Surface	chemistry	 PEG-NH2/PEG	7.Surface	charge	(zeta	potential)	 -36.0	mV		
8.Solubility/dispersibility	 ≧9.3	mg	PDA	/	ml	(in	10%	sucrose)	Well	dispersed	after	reconstitution		
	
2.2.2.	Transmission	electron	microscopy	(TEM)			Images	of	nanoparticles	were	obtained	using	a	transmission	electron	microscope	(TEM,	Hitachi	model	H-7650)	using	an	acceleration	potential	of	100	kV.	Samples	were	prepared	by	 layering	 the	nanoparticles	suspension	on	a	copper	grid	followed	by	negative	staining	for	10	sec	with	freshly	prepared	and	sterile-filtered	2%	(w/v)	uranyl	acetate	solution.	The	TEM	results	are	depicted	in	Figure	2	and	Table	3.	
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	Figure	2:	TEM	and	DLS	characterization	of	PLA-DSPE-PEG	NPs.	Transmission	electron	microscopic	(TEM)	images	of	PLA-PEG	NPs	with	nominal	diameter	up	to	100	nm	corresponding	to	the	scale	bar	seen	in	the	bottom	right	corner	of	the	image.		The	particle	size	distribution	determined	by	dynamic	light	scattering	(DLS)	and	TEM	are	shown.	The	zeta	potential	was	-36.0	mV.					
2.2.3.	Particle	size	and	zeta	potential	measurements	Hydrodynamic	diameter	and	zeta	potential	of	PLA-PEG	nanoparticles	were	measured	using	a	particle	size	analyzer	(NanoBrook	90Plus,	Brookhaven	Instruments	Corp.,	Holtsville	NY)	and	zeta	potential	analyzer	(NanoBrook	 ZetaPALS,	 Brookhaven	 Instruments	 Corp.)	 equipped	with	 a	 660-nm	 laser.	 	 The	measured	delay	 time	correlation	 functions	were	 fitted	 to	a	non-negative	 least	 squares	 (NNLS)	model	 to	 calculate	particle	size	distribution.	The	DLS	results	are	depicted	in	Figure	2	and	Table	3.		Table	3:	Table	of	Nanoparticle	Properties		
System	 Surfactant	 Indicator	 Location	of	indicator	
Mean	
diameter	
(nm)	
Zeta	
potential	
(mv)	
Animal	 Dose	(ug)	
Delivery	
method	Polymer-micelle	(PLA-DSPE-PEG)	 None	 Zr89	 Covalently	linked	(Amde	linked)	 50-150	 -36	 Sprague-Dawley	 25	 IN	or	IV	
	
2.2.4.	Quantitative	determination	of	DSPE-PEG	DSPE-PEG	was	measured	calorimetrically	with	ammonium	ferrothiocyanate	method	(11)	(15).		Samples	were	dissolved	in	1	ml	chloroform	and	mixed	with	1	ml	of	ammonium	ferrothiocyanate	reagent	(30	mg/ml	ammonium	thiocyanate	and	27	mg/ml	iron	chloride	hexahydrate).		The	mixed	solution	was	shaken	for	3	min	and	centrifuged	at	1,000	xg	and	 the	 red	 lower	 layer	was	 collected.	 	The	DSPE-PEG	derivative	was	determined	at	470	nm	absorbance	using	a	spectrophotometer	(DU800,	Beckman	Coulter).		
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2.2.5.	PLA	quantification		Lyophilized	 sample	 was	 dissolved	 in	 stabilized	 tetrahydrofuran	 and	 20	 μl	 aliquot	 was	 analyzed.		Chromatographic	separation	was	performed	on	a	gel	permeation	chromatography	system	connected	to	a	refractive	 index	detector	 (Agilent	1100	series)	with	a	PLgel	MIXED-D	column	(300	mm×75	mm,	5	μm,	Agilent).	 	 PLA	was	 eluted	 by	 100%	 tetrahydrofuran	 at	 a	 1	ml/min	 of	 flow	 rate	 and	 PLA	 content	was	determined	by	peak	area	of	refractive	index	signal.		
2.2.6.	Radiolabeling	of	PLA-PEG	NPs	with	89Zr	Zirconium	89	(89Zr)	was	produced	with	a	cyclotron	at	Washington	University	at	St.	Louis	and	overnight	shipped	to	our	institution	for	nanoparticle	tagging.	For	89Zr-labeling,	PLA-PEG	NPs	were	first	conjugated	with	a	derivative	of	desferrioxamine	(DFO-Bz-NCS)	through	amide	formation.	Specifically,	1.55	mg	PLA-PEG	NPs	were	stirred	with	0.02	mg	DFO-Bz-NCS	in	water	for	an	hour.	Purification	(molecular	weight	cut-off	(MWCO)	100kD)	was	done	at	8,000	rpm	with	a	centrifugal	concentrator	(Vivaspin	500	GE	HealthCare)	and	 washed	 with	 HEPES	 (4-(2-hydroxyethyl)-1-piperazineethanesulfonic	 acid)	 buffer.	 Before	radiolabeling,	the	PLA-PEG	NPs	were	neutralized	with	89Zr-oxalate	by	using	1M	NaOH	in	HEPES	buffer	and	a	final	pH	of	7.4	was	obtained.	Radiolabeled	PLA-PEG	NPs,	89Zr	(1	mCi)	were	added	to	0.4	mg	of	PLA-DFO	and	incubated	in	pH	7.4	HEPES	buffer	for	30	minutes.	Radiolabeled	PLA-PEG	NPs	were	then	purified	by	centrifugation	and	the	labeling	efficacy	was	measured	with	an	instant	thin	layer	chromatography	(ITLC)	autoradiogram.	The	 radiolabeling	 activity	was	650	µCi	per	1	mg	of	PLA-PEG	NPs.	Details	 of	 zirconium	tagging	of	NPs	are	listed	in	Table	4.		Table	4:	Zirconium-NP	tagging	details	 			
	
	
	
	
2.7.		INDD	and	IV	delivery	techniques	For	the	INDD	technique,	an	adult	male	rat	(300-500g)	rat	was	placed	into	a	9	x	18	in	custom	induction	chamber	and	anesthetized	with	4%	 Isoflurane	 (Figure	3).	The	animal	was	weighed	and	 the	amount	of	radioactivity	in	the	nanoparticle	solution	was	measured	in	a	dosimeter.	Custom	made	slots	in	the	side	of	the	induction	chamber	allowed	for	manipulation	of	the	animal,	which	was	placed	in	a	supine	position.	A	PE	10	sized	nasal	catheter	was	inserted	2	cm	deep	into	the	right	nostril	and	attached	to	a	½	cc	Tuberculin	syringe.	1.67	µg/1	ul	saline	of	100	nm	PLA-PEG-Zr89	NPs	were	delivered	over	30	s	for	a	total	of	25	ug	PLA-PEG-Zr89	NPs	delivered	 into	 the	dorsal	 and	posterior	aspect	of	 the	 right	nasal	 cavity.	After	delivery,	 a	syringe	containing	NPs	was	re-measured	in	a	dosimeter	to	ensure	accurate	delivery	of	100	µCi.	For	the	IV	delivery	technique,	animals	were	anesthetized	using	isoflurane	via	mask	ventilation.	3%	isoflurane	was	delivered	until	complete	absence	of	reflexes.	The	tail	vein	was	cannulated	and	25	ug	of	NP	solution	was	administered	intravenously	through	a	½	cc	Tuberculin	syringe	slowly	manually	over	several	seconds.			
Parameter	 Result	Volume	 1.2	mg	NP	suspended	in	120	ul	of	0.9%	saline	Activity	 967	uCi	Percent	isolated	yield	 60%	non-decay	corrected	yield.	
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		Figure	3:	INDD	delivery	technique.	Each	rat	was	placed	in	an	induction	chamber,	anesthetized	and	placed	in	a	supine	position.	Tubing	was	threaded	into	the	induction	chamber	through	a	small	custom-made	hole	drilled	on	the	side	and	carefully	inserted	2	cm	deep	into	the	dorsal	nasal	cavity.	The	NP	solution	was	delivered	via	a	syringe	pump	over	a	30	second	period.			
	
2.2.8	PET/CT	imaging	The	animals	were	sacrificed	using	a	humane	IACUC	approved	protocol,	transported	to	the	human	PET/CT	scanner	and	 imaged.	The	PET/CT	 imaging	studies	were	carried	out	 in	a	Siemens	mCT	PET/CT	scanner	(model:	Biograph	mCT	S	(64)-4R	Software	version	VG	51C).	Each	animal	was	scanned	in	two	fifteen	minute	sessions	sequentially	with	the	upper	half	of	the	animal	imaged	first	followed	by	the	lower	half.		The	FOV	for	1	bed	was	216	mm,	with	overlap	the	2	beds	covered	347	mm.	Computer	tomography	(CT)	imaging	of	animals	was	performed	followed	by	co-registration	of	PET	images	(MIM	Version	6.6.5	(MIM	Software	Inc.,	Cleveland,	OH,	http://www.mimsoftware.com/).			
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2.2.9	Organ	procurement	and	Gamma	counting	For	the	organ	procurement	experiments,	100	nm	PLA-DSPE-PEG	NPs	were	labeled	with	zirconium.	2	mg	NP	were	suspended	in	140	ul	of	0.9%	saline.	A	65%	non-decay	corrected	yield	was	obtained	during	the	labeling.	 100	 nm	 PLA-DSPE-PEG	 NPs	 were	 delivered	 at	 30	 min	 and	 1	 hr	 following	 INDD	 or	 IV	administration.	The	rats	were	deeply	anesthetized	with	isoflurane	and	placed	in	a	dissection	tray.	The	skin	of	the	abdomen,	chest	and	neck	shaved	and	right	external	jugular	vein	were	exposed.	A	sub-diaphragmatic	approach	was	followed	by	open	thoracotomy.	The	Apex	of	LV	was	lancinated	and	feeding	needle	(+syringe)	was	placed	into	ascending	aorta.	A	clamp	was	placed	over	feeding	needle	to	prevent	reflux	of	blood	from	the	LV.	The	right	external	jugular	vein	was	ligated	while	saline	was	pumped	through	beating	heart.	50	ml	saline	was	 infused	 to	 flush	 the	blood	 (exsanguination).	The	organs	were	dissected,	 isolated,	washed	 in	saline	 and	 placed	 into	 gamma	 counting	 tubes	 (Brain,	 liver,	 lungs,	 kidneys,	 spleen,	 heart,	 intestines,	stomach).	Data	was	collected	and	entered	into	an	excel	sheet	and	represented	as	CPM/g	weight	of	each	organ.			
3.	Results:	During	phase	1	(Figure	1),	we	produced	two	sets	of	NPs	(Table	1).	The	first	NP	is	a	100	nm-sized	polymer	micellar	NP	made	of	Poly-D,	 L-lactide	 (PLA),	 1,2-distearoyl-sn-glycero-3-phosphoethanolamine	 (DSPE),	and	polyethylene	 gylocol	 (PEG)	 to	 form	a	100	nm-sized	PLA-DSPE-PEG	NP	 (Bio	Ma-Tek,	Bio	Materials	Analysis	Technology	Inc.,	http://www.bioma-tek.com/,	Hsinchu	County,	Taiwan).	The	polymer	component	of	the	NP	contains	the	ability	to	encapsulate	a	drug	agent.	The	DSPE	provides	stabilizing	properties.	The	outer	PEG	contains	hydrophilic	and	stealth	properties.	For	a	subset	of	PEG	molecules,	an	amino	group	was	added	to	the	surface	to	provide	20%	end	amino	groups	for	eventual	conjugation	with	tagging	agents.	The	NPs	 were	 characterized	 in	 vitro	 using	 transmission	 electron	 microscopy	 (TEM)	 and	 dynamic	 light	scattering	(DLS).	The	mean	hydrodynamic	diameter	of	the	NPs,	which	is	closest	to	the	true	mean	diameter	in	physiologic	milieu,	was	100	nm	with	a	diameter	range	of	50-100	nm.	The	zeta	potential	was	measured	to	be	-36.	(Tables	2	and	3	and	Figure	2).	
	The	PLA-DSPE-PEG	NPs	and	PBD	micellar	NPs	were	prepared	for	tagging	with	Zr89	by	first	conjugating	a	derivative	 of	 desferrioxamine	 (DFO-Bz-NCS)	 through	 amide	 or	 carboxyl	 bonding.	 Using	 techniques	developed	and	tested	in	the	RSNA	Resident	Grant	project,	Zr89	labeled	PLA-PEG	NPs	were	generated	and	purified	by	centrifugation.	Labeling	efficacy	for	our	most	recent	studies	was	determined	(Approx.	60%)	with	an	instant	thin	layer	chromatography	(ITLC)	autoradiogram	(Table	4).			For	phase	2	(Figure	1),	12	animals	have	been	studied	to	date	using	either	Ex	Vivo	PET/CT	imaging	or	organ	procurement	following	IV	delivery	or	INDD	at	various	time	points.	Figure	3	depicts	the	set	up	for	INDD	using	a	custom-built	induction	chamber.	For	intravenous	delivery,	the	tail	vein	was	identified	and	accessed.			For	phase	3	(Figure	1),	a	total	of	8	animals	were	administered	the	100	nm	PLA-DSPE-PEG	NPs,	sacrificed	without	tissue	perfusion	or	exsanguination	and	imaged	under	the	clinical	mCT	PET/CT	scanner	following	NP	delivery.	PET/CT	scanning	was	consistent	in	all	cases	with	15	min/PET	acquisitions	(2	acquisitions	of	half	body	due	to	crystal	array	size	Using	the	PET	and	CT	image	acquisition	and	co-registration	software	(Siemens	Biograph	mCT	Software	version	VG	51C)	images	were	obtained	and	fused	using	MIM6	clinical	software	 (v6.6.5,	MIM	Software	 Inc,	 Cleveland,	OH	 (MIM	Software	 Inc.,	 http://www.mimsoftware.com)	Figure	4	 shows	a	 representative	 animal	 following	 INDD.	Using	 the	MIM6	program,	quantitative,	 three-dimensional	regions	of	interest	(3D	ROI)	were	created	for	select	organs	which	were	commonly	studied	in	more	 recently	 published	 nanoparticle	 biodistribution	 studies	 (12)	 (Figure	 5).	 The	 whole	 body	 (WB)	activity	as	well	as	brain,	nasal	cavity,	esophagus,	stomach,	intestines,	lungs,	liver,	spleen,	and	kidney	organ	
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activity	were	determined	in	Becquerel/ml	after	adjusting	for	animal	weight,	initial	administered	dose,	and	adjusted	 dose	 after	 time	 decay.	 The	 percent	 activity	 in	 the	 individual	 organ	 was	 calculated	 based	 on	comparison	with	whole	body	activity	and	these	results	are	depicted	for	all	measured	organs	in	Figure	6	and	the	brain	in	Figure	7. Representative images of nasal cavity and brain activity are shown in Figure 8.	
	
	
	
	Figure	4:	Representative	PET/CT	images	at	1	Hr	following	INDD	of	100	nm	PLA-DSPE-PEG	NPs	tagged	with	Zr89.	Two	coronal	images	showing	activity	in	various	organs,	most	notably	the	nasal	cavity/brain	interface,	esophagus,	stomach	and	intestines	as	would	be	expected	post-INDD.	
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	Figure	5:	Representative	organ	region	of	interest	analysis	using	MIM6	software	of	a	single	animal	following	INDD	of	100	nm	PLA-DSPE-PEG	tagged	with	Zr89.	Organs	and	their	respective	colors	are	shown	on	the	left	panel.	PET	images	are	shown	on	top	and	fusion	images	of	PET	with	CT	are	shown	on	the	bottom.		
	
	Figure	6:	Ex	Vivo	PET	activity	in	various	organs	at	30	Min	and	1	Hr	following	intravenous	delivery	of	100	nm	PLA-DPSE-PEG	NPs	tagged	with	Zr89.	Activity	following	INDD	was	greatest	as	expected	in	the	nasal	cavity	and	along	the	GI	 tract.	 Following	 IV	 delivery,	 activity	 was	 greatest	 in	 the	 lung	 capillary	 beds,	 liver,	 spleen	 and	 intestines.	Comparatively	less	signal	was	seen	in	the	brain,	heart	and	kidneys.		
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	 Figure	7:	Zr89	activity	in	the	brain	at	30	minutes	and	1	hour	following	both	IV	delivery	and	INDD	of	100	nm	PLA-DSPE-PEG	NPs.	Overall	brain	activity	following	IV	and	INDD	was	low	when	depicted	as	percent	of	total	body	activity.	However,	there	was	much	greater	activity	in	the	brain	following	INDD	compared	with	IV	delivery.	Brain	activity	decreased	at	1	Hr	compared	to	30	minutes	in	both	INDD	and	IV	treated	animals.				
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	Figure	8:	PET	activity	in	the	Head/neck	and	brain	in	a	rat	at	30	minutes	following	administration	of	100	nm	PLA-DSPE-PEG	NPs.	A.)	Coronal	image	through	the	posterior	cranium	shows	intense	activity	in	the	oropharynx	but	also	activity	in	the	brain	limited	to	the	cranial	contour.	B.)	Coronal	MRI	of	a	different	rat	through	the	same	regions	as	in	image	A	demonstrates	better	soft	tissue	delineation.	The	brainstem	pons	and	cerebellum	as	well	as	the	middle	cerebellar	peduncles	are	well	visualized	which	corresponds	to	the	region	of	activity	in	A.	C.)	Axial	image	through	the	brain,	skull	and	nasal	cavity.	Note	the	intense	activity	in	the	nasal	cavity.	Analysis	of	the	anterior	brain,	including	olfactory	bulbs	is	limited	given	the	high	signal	in	the	nasal	cavity.	
	
	
	During	phase	4	(Figure	1),	the	organs	of	a	total	of	four	animals	were	procured	following	both	IV	delivery	and	 INDD.	Animals	were	sacrificed	by	 intra-cardiac	perfusion	at	either	30	minutes	or	1	hour	 following	either	IV	delivery	or	INDD.	The	animals	underwent	exsanguination	via	ligation	of	the	internal	jugular	vein	to	minimize	blood	pool	contamination	of	the	procured	organs.	The	organs	were	rinsed	in	saline,	weighed	and	activity	measured	in	the	gamma	counting	machine.	Given	the	small	size	of	the	tube	needed	for	gamma	counting,	only	portions	of	the	stomach	and	intestines	were	able	to	fit	into	the	tubes.	Figure	9	demonstrates	a	 similar	 distribution	 of	 activity	 as	 seen	 on	 PET/CT	 with	 the	 samples	 represented	 as	 counts	 per	minute/gram	of	tissue	(CPM/g	tissue).			
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	 Figure	9:	Gamma	counter	 activity	 in	various	organs	at	30	Min	and	1	Hr	 following	 intravenous	delivery	of	100	nm	PLA-DPSE-PEG	NPs	tagged	with	Zr89.	Based	on	published	review	by	Simon	et	al.,	 2014,	 selected	 organs	 included	 brain,	 lungs,	 heart,	 liver,	 spleen,	 kidneys,	 stomach	 and	intestines.	Nasal	cavity	and	esophagus	were	not	measured	by	gamma	counter.	In	addition,	only	a	portion	 of	 the	 stomach	 and	 a	 portion	 of	 the	 intestines	 would	 fit	 into	 the	 gamma	 counter	 for	measurement.		
	
	
4.	Discussion:	
	The	 findings	 reported	 in	 this	 study	 illustrate	 that	 whole	 body	 biodistribution	 can	 be	 performed	with	radiolabeled	nanoparticles	administered	via	the	intranasal	(or	intravenous)	routes	in	the	ex	vivo	rat	using	a	 clinical	 PET/CT	 scanner.	Whole	 body	measurements	were	 obtained	 and	 compared	with	 initial	 dose	administration	and	were	found	to	be	within	10%	of	initial	administered	dose.		 	By	PET/CT,	strong	activity	was	visualized	in	the	nasal	cavity	and	pharyngo-esophagus	at	30	minutes	after	INDD,	similar	to	that	found	by	Shingaki	et	al.,	2016	(13).	Moderate	activity	was	visualized	in	the	nasal	cavity	and	 pharyngo-esophagus	 at	 1	 hour	 after	 INDD	with	 scant	 activity	 appearing	 in	 the	 stomach,	 liver	 and	intestines.	 	Following	organ	procurement,	 intranasally	delivered	NPs	 tagged	with	Zr89,	 the	majority	of	activity	measured	within	the	eight	standard	organs	(not	nasal	cavity	or	esophagus)	was	detected	in	the	stomach	at	30	minutes	and	intestines	at	1	hour.	This	is	intra-luminal	activity	from	having	been	swallowed	and	is	a	major	limitation	of	liquid	based	solutions	utilized	in	INDD.	Aerosolized	compounds	would	greatly	limit	such	substantial	loss	of	NPs	along	the	GI	tract.	Note	that	activity	in	the	nasal	cavity	and	esophagus	were	measured	during	organ	procurement	since	their	procurement	is	technically	challenging	and	readily	demonstrated	on	PET/CT	imaging.	Contrary	to	what	was	expected,	only	low	levels	of	activity	compared	to	
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IV	delivery	were	found	in	the	lungs	indicating	the	animal	did	not	aspirate	the	NPs	while	under	anesthesia.	Very	low	levels	were	found	elsewhere,	including	the	brain,	especially	after	1	hour.			Based	on	our	data	at	30	minute	and	1	hour	after	INDD	of	100	nm	PLA-DSPE-PEG	NPs	(Figure	7),	from	1-1.5%	 zirconium	 activity	 is	 visualized	 the	 brain,	 consistent	with	 published	 literature	 (14-16).	 Figure	 9	depicts	a	representative	animal	imaged	30	min	following	Ex	Vivo	imaging	with	PET/CT.	Signal	is	detected	in	the	posterior	half	of	the	brain,	although	at	only	the	lowest	intensity	range.	Additional	much	higher	signal	is	seen	in	the	oropharynx	and	laterally	in	the	anterior	neck	region	corresponding	with	lymph	nodes	and/or	salivary	glands.	Strong	signal	within	the	nasal	cavity	precluded	assessment	of	the	more	anterior	brain	and	olfactory	bulbs	on	this	study.		Strong	activity	was	visualized	in	the	liver	and	lungs	following	IV	delivery.	Signal	persisted	in	the	lungs	1	hour	after	IV	delivery	and	declined	in	the	liver	substantially.	Mild	activity	was	visualized	in	the	spleen	and	intestines	at	30	min	following	IV	delivery.	This	declined	slightly	in	the	spleen	and	intestines	at	1	hour	post	IV	 delivery	 of	 the	 NPs.	 As	 expected,	 relatively	 little	 activity	 was	 seen	 in	 the	 nasal	 cavity,	 esophagus,	stomach,	heart	and	kidneys	at	either	30	min	or	1	hour	after	IV	delivery.	The	organs	analyzed	following	intravenous	 delivery	 correlate	 with	 NP	 biodistribution	 Review	 from	 Simon	 et	 al.,	 2014	 (12).	 Organs	assessed	 across	 multiple	 studies	 in	 this	 review	 included	 the	 brain,	 liver,	 kidney,	 lung,	 spleen,	 heart,	intestine,	and	stomach.	Following	tail	vein	administration	of	NPs	tagged	with	Zr89,	the	majority	of	gamma	counting	activity	measured	within	the	eight	procured	organs	was	detected	both	the	30	min	and	1	hour	time	points	 in	 the	 lungs,	 presumably	 the	 vascular	 capillary	 bed.	 This	 correlated	with	 the	 PET/CT	 data	 and	suggests	possible	aggregation	or	clumping.	Very	little	activity	was	seen	in	the	brain,	stomach,	intestines	or	kidneys	following	intravenous	delivery	in	the	gamma	counting	studies.	The	lungs	are	considered	upstream	of	these	organs	and	could	account	for	low	levels	in	the	other	organs.	Moderate	activity	was	visible	in	the	liver,	spleen	and	blood	pool	of	the	heart.		
	
4.1	Study	Limitations.	Limitations	of	the	study	are	multiple.	This	study	was	performed	ex	vivo	which	cannot	be	performed	using	list	 mode	 format	 and	 therefore	 precludes	 compartmental	 analysis.	 Spatial	 PET	 resolution	 remains	 a	problem	when	analyzing	activity	in	the	anterior	brain	and	skull	base	regions	given	their	close	proximity	to	the	high	signal	in	the	posterior	nasal	cavity	and	oropharynx.	This	was	also	found	to	be	the	case	with	Kamei	et	al.,	2016	as	well	(17).	Brain	subregions	cannot	be	delineated	with	CT	so	MRI	of	a	reference	animal	was	used	to	identify	brain	subregions	in	Figure	8.	Some	organs	on	CT,	such	as	the	spleen	are	not	always	fully	discernable	 from	 adjacent	 organs,	 such	 as	 the	 stomach	 and	 left	 kidney	when	determining	ROI	 activity	measurement.	 ROIs	 definitions	 are	 time	 consuming	 for	 individual	 organs.	 ROIs	 from	MIM	 are	 defined	precisely	pixel	by	pixel	in	3D	with	a	manual	process	guided	by	MRP	images	of	fused	PET/CT.	Difficulties	in	ROI	analysis	arise	 from	Overlap	of	ROIs	since	 they	are	not	mutually	exclusive.	The	 full	extent	of	 larger	organs,	such	as	the	liver,	stomach	and	intestines	are	amenable	to	ROI	analysis	on	PET/CT	but	not	using	gamma	counter	where	small	tubes	used	for	gamma	counting	allow	only	limited	tissue.	This	was	overcome	by	 using	 activity/gram	 of	 tissue	 but	 even	with	 this,	 gamma	 counting	 activity	 of	 organs	 is	 not	 directly	comparable	to	the	PET/CT	activity	for	these	organs.		
Future	Work	Many	nanoparticles/drugs	are	being	studied	using	the	INDD	route	but	very	few	have	made	it	to	clinical	trials.	A	better	understanding	of	the	nose	to	brain	route	is	essential	to	maximize	delivery	of	drugs	using	this	 route.	 Since	 a	 micro-PET/CT	 scanner	 is	 not	 available	 at	 every	 research	 institution,	 we	 show	 the	feasibility	of	using	a	clinical	PET/CT	scanner	to	study	INDD.	In	the	future,	we	plan	to	study	longer	time	points	up	to	24	hours	after	INDD	and	intravenous	delivery	to	determine	the	total	circulating	time	of	the	
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nanoparticles.	 Given	 the	 overall	 low	 rate	 of	 compounds	 entering	 the	 brain	 following	 intranasal	 and	intravenous	delivery,	we	plan	to	work	with	nanoparticle	of	varying	size	and	zeta	potentials.	We	also	will	study	 various	 agents	 known	 to	 aid	 in	 translocation	 across	 membranes	 (Penetration	 enhancers)	 and	reversibly	 open	 tight	 junctions	 (chitosan,	matrix	metalloproteinase	 inhibitors).	We	 also	 plan	 to	 utilize	carbohydrate	targeting	moieties	for	better	nose	to	brain	delivery	(lactoferrin,	odoranolectins).	
	
Conclusion	We	demonstrated	that	a	clinical	PET/CT	scanner	can	be	utilized	to	study	the	whole	body	biodistribution	of	radiolabeled	 nanoparticles	 administered	 intranasally	 to	 the	 rat,	 and	 can	 be	 validated	 using	 organ	procurement	and	a	gamma	counter.	Advanced	imaging	of	INDD	has	the	potential	to	significantly	impact	the	emerging	field	of	radio-nanotheranostics.	
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